Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety

Rebecca S Kristeleit,Terri Cameron,Ana Oaknin,Jonathan A Ledermann,Susan M Domchek,Ronnie Shapira-Frommer,Yvette Drew,Iain A Mcneish,Alexandra Leary,Isabelle Ray-Coquard,Amit M Oza,Sandra Goble,Lara Maloney,Judith Balmaña,Domenica Lorusso

doi:10.1136/ijgc-2019-000623

Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety

Rebecca S Kristeleit, Terri Cameron + Show 13 more

Open Access

https://doi.org/10.1136/ijgc-2019-000623

Copy DOI

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	Publication Date: Nov 1, 2019
Citations: 19	License type: open-access

Affiliation: University College London, London Cancer, Clovis Oncology (United Kingdom), Vall d'Hebron Hospital Universitari, University of Pennsylvania, Sheba Medical Center, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University, Imperial College London, Centre Léon Bérard, Claude Bernard University Lyon 1, Princess Margaret Cancer Centre, University Health Network, Clovis Oncology (United States), Agostino Gemelli University Polyclinic

#High-grade Ovarian Cancer #Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectiveTo report results from an integrated efficacy and safety analysis supporting the European Commission's approval of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy treatment for relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.MethodsEfficacy...

Full Text